Sharp decline in life sciences industry investments in Israel in 2025
A newly published report presents a complex picture of the state of the Health-Tech industry in Israel. While a certain recovery was recorded in the sector in 2024, the latest data for 2025 points to a significant and concerning trend reversal for Israeli companies.
According to the report, there has been a sharp 40% decline in the volume of investments in life sciences companies in Israel during the current year. This is a significant figure indicating the growing difficulty for companies in the field to raise capital from investors, following a period of cautious optimism last year.
In addition to the overall decline in investments, the report points to another trend that has persisted over time: a decrease in the average amount of each deal. This means that even when companies succeed in raising funds, they are receiving lower amounts than before, making it difficult for them to expand their operations and develop new technologies.
Despite the challenging data regarding investments, the report notes that exports in the sector remain stable. This fact indicates that the products and services of Israeli life sciences companies are still in demand in international markets, despite the financial difficulties at the capital-raising stage.
The new data raises questions regarding the future of the industry in Israel. Experts in the field are expected to closely monitor developments in the coming months to understand whether this is a temporary crisis or a long-term shift in investment habits within the health and technology sector.